Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Hansa Biopharma posted Q4 2025 revenue of 76.0 MSEK (up 135% YoY) driven by IDEFIRIX product sales of 61.1 MSEK (+139% YoY); full‑year revenue was 222.3 MSEK (+30%) with product sales of 204.7 MSEK (+46%). The company submitted a BLA to the FDA for imlifidase (requesting Priority Review with a potential PDUFA in August 2026), completed a directed share issue raising 671.5 MSEK, and held 701.1 MSEK in cash and short‑term investments. Despite a full‑year loss of 529.3 MSEK (EPS -6.52 SEK), the stronger commercial uptake, improved liquidity from the equity raise, and the near‑term regulatory catalyst materially improve the outlook for a U.S. launch while the company continues to invest in R&D and pipeline development.

Analysis

Market structure: Hansa (HNSA.ST) is the direct beneficiary of a near-term regulatory binary (BLA acceptance/PDUFA) and a strengthened balance sheet (cash + short‑term investments 701.1 MSEK after a 671.5 MSEK directed issue). Q4 product sales +139% y/y and FY +46% indicate demand in Europe but total addressable US volume for highly sensitized deceased‑donor kidney transplants is likely modest (single‑digit % of transplant pool), implying high pricing power but limited absolute volume initially. Gene‑therapy pretreatment data broaden optional demand but is early and small‑population.

Risk assessment: Key tail risks are FDA non‑acceptance/CRL (timing: ~60 days from submission) or restrictive label/payer carve‑outs post‑approval; manufacturing scale or unexpected safety signals are second‑order risks that could force costly post‑marketing studies. Financially, FY net cash used in operations ~549 MSEK vs cash 701 MSEK gives ~12–18 months runway at current burn (but directed issue reduces near‑term dilution risk); watch for further raises if commercialization costs ramp faster. Catalysts: FDA filing acceptance (~Mar–Apr 2026), Priority Review decision, PDUFA (potential Aug 2026) and US launch/commercial contracts.

Trade implications: Tactical long exposure to HNSA is favored into regulatory readouts but size it: initial small base (2–4% portfolio) expanding on a positive 60‑day accept decision. Use defined‑risk options to play the PDUFA (buy Sep/Oct 2026 call spreads sized to ≤1–2% of portfolio) and hedge with tight puts after acceptance. Pair trade: long HNSA vs short IBB (iShares Nasdaq Biotechnology ETF) to isolate idiosyncratic approval upside while hedging sector volatility.

Contrarian view: Consensus overlooks the dilution and limited US patient pool — outstanding shares jumped ~50% (67.8M→101.8M), capping per‑share upside; payers may demand outcome data or narrow coverage. Conversely, market may underprice gene‑therapy optionality: if imlifidase becomes standard AAV antibody removal, upside beyond transplant could be material over 2–5 years. Watch hospital formulary decisions and first‑12‑month US uptake as the real demand test.

Key Decisions for Investors

• Establish a 3% long position in Hansa Biopharma (HNSA.ST) within the next 2–4 weeks to capture upside into the FDA 60‑day filing acceptance (~Mar–Apr 2026); set a hard stop at -30% and trim to 50% of the position on a >30% rally post‑acceptance.
• Allocate 1% of portfolio to a defined‑risk options trade: buy a Sep/Oct 2026 bull call spread on HNSA (to capture PDUFA upside around Aug 2026) sized so max loss = 1% portfolio; add a small protective put (6–8% notional) if acceptance is announced.
• Implement a pair trade: long HNSA 3% vs short IBB 2% (ticker IBB) to isolate company‑level FDA/cutting‑edge adoption upside while hedging broader biotech volatility through Aug 2026.
• If FDA issues a CRL or requests major additional studies, exit long positions fully and consider shorting healthcare small‑cap names with weak cash runway; conversely, on approval/PDUFA positive, increase HNSA exposure to 6% and take partial profits after a 40–60% post‑approval rally.